We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

August 14, 2018

The Consumer Oncology Revolution

Commentary
Sophie Madden
&

There has been much hype around healthcare consumerism lately, with direct-to-consumer digital health and wellness apps coming into the market at unprecedented rates - But can we really trust patients to filter through this noise and find true value? The booming industry of direct-to-consumer oncology solutions has clear benefits for patients who are aware of the solutions and willing to engage, but for mass adoption and scalability to occur, there needs to be greater awareness of these offerings available to the healthcare fraternity and wider public.

From Patient to Savvy Consumer ?

Within other industries where there has been a similar shift towards direct-to-consumer technologies, we have seen that value for money is one of the biggest things consumers seek. However, when it comes to healthcare, the end goal for the consumer is rarely just a cost reduction - they want to know that these solutions are actually benefiting their health too. This end goal is even more niche when it comes to the cancer consumer, with improved quality of life being top priority.

It’s in the DNA

Direct-to-consumer genetic testing has exploded in the last few years, with companies expanding their offerings to include a broad range of health, ancestry, and lifestyle information. Helix, for example, now offer a test called Vinome, where you receive wine recommendations ‘uniquely tailored to your taste preferences and scientifically selected based on your DNA’. Helix, Ancestry.com, and MapMyGenome can tell you information about your physical traits, how well you metabolize certain foods, how good you are at sports etc...the list goes on.

Sifting through this saturated market and trying to find the real value for consumers in terms of health related insights can seem challenging. Where the usefulness lies is in genetic testing that can lead to improved clinical outcomes for patients who are at risk of certain diseases based on their DNA. Putting the power in the hands of the consumer might be considered risky business, but if patients are becoming actively engaged in their own health and this leads to earlier detection and diagnosis, then we should be embracing these technologies.

When it comes to actual health related insights, 23andMe are largely recognised as the leading genetic testing company, having over 5,000,000 users of their service since they began offering their home genetic testing kits in 2006. In March of this year, 23andMe broke ground when they announced that they had received the first-ever FDA authorization for a direct-to-consumer genetic test for cancer risk. Through 23andMe, people can now test for three genetic variants found on the BRCA1 and BRCA2 genes known to be associated with higher risk for breast, ovarian and prostate cancer. It won't be long until we see other companies following suit and seeking the coveted FDA stamp of approval for similar genetic tests.

Better Together - Patient support solutions

There are opportunities for direct-to-consumer solutions within oncology from prevention to care through survivorship. In particular, we have seen a growing number of patient support and self-management solutions being developed. Patients who receive a cancer diagnosis can be overwhelmed with information regarding their condition, treatment, medication plan, check-ups and appointments. Digital solutions can offer patients services to aid with the management of their condition and connect them to other patients going through a similar experience. The CancerAid solution is a great example of this. Cancer Aid helps patients store all their treatment and diagnostic information in one place, access medically accurate peer reviewed information, track and manage their symptoms and medication effectiveness, connect with others going through similar experiences, and keep up to date with cancer news and research. CancerAid also has a component in which healthcare providers can use the solution to monitor their patients remotely and gain insights around symptom management and medication adherence.

CancerGraph is another solution that helps people to track symptoms and side effects of their cancer. App users can choose from cancer types, medications and concerns, and can peruse a list of over 200 symptoms and side effects to pull into their personal profile. CancerGraph then distills the data into a report users can view on their phone and email to their doctor.

Smart PatientsPatientsLikeMe and Healthunlocked are all online communities for patients who are going through an illness, with strong oncology communities established in each. These platforms allow patients to share information about their condition, learn from others going through similar conditions, and be supported by an online community. Some even offer services where patients can find out about the latest treatments regarding their specific type of cancer, and discover clinical trials they may be eligible for.

The benefits of these solutions for cancer patients are obvious, from being more engaged in their health, to improved symptom management and medication adherence, to facilitating more informed conversations with their physician.

Viva la Revolution

The growing number of direct-to-consumer solutions currently available within the oncology space is beneficial for patients who actively want to get involved in their health and know where to find the technology, but at the end of the day if this is really going to revolutionise cancer care, these solutions need to be more easily obtainable, with greater awareness of their offerings available to the healthcare fraternity and wider public.

While uptake from other patients and recommendations from family members can increase awareness and use of these solutions, mass adoption and scaling will likely only happen when physicians begin to discuss the technology to their patients.The sweet spot is where healthcare providers embrace these direct-to-consumer solutions as facilitators for a better experience and better care for the patient, which ultimately is the end goal for all involved.

Public interest around companies like 23andMe should be welcomed, recognising the fact that people taking an active interest in their own health can facilitate earlier detection and diagnosis. These solutions shouldn't live in isolation in a consumer world, where patients are unsure how to action the information they receive, but instead be welcomed by the health care fraternity, who understand the necessity for counselling and medically informed conversations for patients who discover they are at risk for a certain cancer, and encourage the the initiative to invest in their own health.

Here’s a call to pharma and HCPs to help consumers navigate through this field to find medically accurate insights and enable these consumer facing solutions to become an integral component of the cancer care journey.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

DTx last mile delivery - HCPs and patients adoption

2nd November @ 11:45AM EDT

Join us in this informal conversation where we will discuss the main challenges around HCP and Patient adoption of DTx. Apply now to connect with peers and learn from fellow thought leaders in this space.

Featuring
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Featuring
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Tech Giants, Start-ups or Incumbents, who will disrupt healthcare?

4th November @ 11:30AM EDT

Join our Digital Health Meeting as discuss How do we define disruption in the healthcare industry? What is the ‘extinction event’ healthcare needs and why has it not happened yet? And what are the learnings from Tech Giants’ moves in healthcareApply now to join the conversation and share your thoughts on the topic.

Featuring
Amanda Goltz
Amanda Goltz
Principal, Business Development, Alexa Health & Wellness at Amazon
Anish Shindore
Anish Shindore
Head of NeuroTech & Open Innovation, Biogen
Featuring
Amanda Goltz
Amanda Goltz
Principal, Business Development, Alexa Health & Wellness at Amazon
Anish Shindore
Anish Shindore
Head of NeuroTech & Open Innovation, Biogen
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: How to get your DTx product reimbursed in the US?

4th November @ 11:45AM EDT

Are you a DTx company seeking reimbursement in the US? Then this masterclass is for you. Join us in this US-focused interactive masterclass led by Mike Pace, who will walk us through how to get your DTx product reimbursed in the US.

Featuring
Michael Pace
Michael Pace
Founder and President at PalmHealth.co
Featuring
Michael Pace
Michael Pace
Founder and President at PalmHealth.co
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: DiGa - Entering the digital health space in Germany

10th November @ 10:45AM EDT

Join us in this interactive masterclass led by Flying Health, as they discuss what you need to know to navigate the DiGa framework. Apply now to learn valuable insights from thought leaders in this space.

Featuring
Laura Nelde
Laura Nelde
Startup Relationship Manager at Flying Health
Len-Philipp Ortlepp
Len-Philipp Ortlepp
Junior Startup Relationship Manager, Flying Health
Featuring
Laura Nelde
Laura Nelde
Startup Relationship Manager at Flying Health
Len-Philipp Ortlepp
Len-Philipp Ortlepp
Junior Startup Relationship Manager, Flying Health

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

DTx last mile delivery - HCPs and patients adoption

2nd November @ 11:45AM EDT

Join us in this informal conversation where we will discuss the main challenges around HCP and Patient adoption of DTx. Apply now to connect with peers and learn from fellow thought leaders in this space.

Featuring
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Featuring
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Telemedicine & Virtual Care Delivery
Telemedicine & Virtual Care Delivery
Telemedicine & Virtual Care Delivery
Telemedicine & Virtual Care Delivery

Commercialisation models for Virtual Care in Respiratory Diseases

3rd November @ 11:45AM EDT

Join our Digital Health Meeting as we discuss commercialisation models for Virtual Care in Respiratory Diseases. Apply now to hear from fellow peers in this space and share your own thoughts and experiences on this topic.

Featuring
Peter Small
Peter Small
Chief Medical Officer, Hyfe
Caleb Bank
Caleb Bank
Product Marketing at NuvoAir
Featuring
Peter Small
Peter Small
Chief Medical Officer, Hyfe
Caleb Bank
Caleb Bank
Product Marketing at NuvoAir
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Tech Giants, Start-ups or Incumbents, who will disrupt healthcare?

4th November @ 11:30AM EDT

Join our Digital Health Meeting as discuss How do we define disruption in the healthcare industry? What is the ‘extinction event’ healthcare needs and why has it not happened yet? And what are the learnings from Tech Giants’ moves in healthcareApply now to join the conversation and share your thoughts on the topic.

Featuring
Amanda Goltz
Amanda Goltz
Principal, Business Development, Alexa Health & Wellness at Amazon
Anish Shindore
Anish Shindore
Head of NeuroTech & Open Innovation, Biogen
Featuring
Amanda Goltz
Amanda Goltz
Principal, Business Development, Alexa Health & Wellness at Amazon
Anish Shindore
Anish Shindore
Head of NeuroTech & Open Innovation, Biogen
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: How to get your DTx product reimbursed in the US?

4th November @ 11:45AM EDT

Are you a DTx company seeking reimbursement in the US? Then this masterclass is for you. Join us in this US-focused interactive masterclass led by Mike Pace, who will walk us through how to get your DTx product reimbursed in the US.

Featuring
Michael Pace
Michael Pace
Founder and President at PalmHealth.co
Featuring
Michael Pace
Michael Pace
Founder and President at PalmHealth.co

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.